Fully Acoustic Liquid Handling Solution
Acoustic Tube Racks

Source Plates

Assay-ready Plates

Featuring the New Access Dual Robot System
Setting new standards for sample integrity, sample management efficiency, and data quality
Sample management is the linchpin of any discovery process. For screens to be run effectively, the sample library must be uncompromised. Labcyte’s sample management solutions dramatically reduce sample volume requirements without sacrificing precision.
The introduction of acoustic tubes enables fully acoustic sample management workflows and offers all the benefits of tip-less liquid transfer, starting at sample preparation. Acoustic tubes coupled with the Echo 655T Liquid Handler and Access Dual Robot System offer superior results for sample management applications.
Primary screening workflows benefit from a completely acoustic liquid handling solution, eliminating the risk of sample contamination or loss. Sample transfers can be made directly from source acoustic tubes to source plates or assay-ready plates.
Whether you are verifying targets by re-screening hits or creating dose response curves, acoustic sample management workflows will validate hits 8x faster. The ability to cherry-pick only indentified hits into a tube rack prevents unnecessary freeze-thaw cycles and risk of hydration or evaporation due to exposure to environment.
Process 625 tube racks instead of 5,209 384-well source plates, when screening 2,000,000 compounds at a 3% hit rate
Create curves and intermediate dilutions directly from tubes, avoiding sample carryover, and cross-contamination
FEATURED ARTICLE
February 2018
Dr. Clive Green and Dr. Philip Spencer
AstraZeneca
Drug discovery is undergoing a transformation powered by advances that provide more knowledge from biological assays, allow for screening orders of magnitude more molecules and enable smarter selection of compounds.
We are on the cusp of having previously unimaginable amounts of information about each target and many more targets to prosecute. For instance, last year AstraZeneca launched an integrated genomics initiative through which scientists will investigate data from as many as two million human genomes, including more than 500,000 from clinical trials run by the company.
READ ARTICLE